|1.||Gozes, Illana: 14 articles (07/2014 - 10/2009)|
|2.||Morimoto, Bruce H: 4 articles (07/2014 - 01/2012)|
|3.||Gold, Michael: 4 articles (07/2014 - 01/2012)|
|4.||Stewart, Alistair J: 3 articles (07/2014 - 01/2012)|
|5.||Giladi, Eliezer: 3 articles (08/2013 - 07/2010)|
|6.||Bhargava, Kalpana: 2 articles (11/2014 - 06/2011)|
|7.||Das, Mainak: 2 articles (11/2014 - 06/2011)|
|8.||Williams, David R: 2 articles (07/2014 - 01/2012)|
|9.||Hirman, Joe: 2 articles (07/2014 - 01/2013)|
|10.||Lorenzl, Stefan: 2 articles (07/2014 - 01/2012)|
|1.||Schizophrenia (Dementia Praecox)
06/01/2013 - "Davunetide has recently demonstrated modest functional improvement in a study of people with schizophrenia. "
06/01/2013 - "Future clinical and preclinical studies are needed to fully define the mechanism of action and cognitive effects of davunetide in schizophrenia."
04/01/2012 - "This study investigates effects of davunetide on cognition in schizophrenia. "
06/01/2013 - "Of 63 outpatients with schizophrenia who received randomized davunetide (5 and 30 mg/day) or placebo in the parent clinical trial, 18 successfully completed (1)H-MRS in dorsolateral prefrontal cortex (DLPFC) at baseline and at 12 weeks. "
04/01/2012 - "Sixty-three subjects with schizophrenia received davunetide at one of two different doses (5, 30 mg) or placebo for 12 weeks in a multicenter, double-blind, parallel-group randomized clinical trial. "
|2.||Alzheimer Disease (Alzheimer's Disease)
01/01/2013 - "These data suggest that AL-108 was generally safe, well tolerated and merits additional investigation as a treatment for Alzheimer's disease."
04/01/2012 - "Davunetide (AL-108, NAP) is an intranasally administered peptide currently being developed for treatment of Alzheimer's disease and related disorders. "
10/01/2009 - "Phase IIa clinical results have recently shown that AL-108 has a positive impact on memory function in patients with amnestic mild cognitive impairment (aMCI), a precursor to Alzheimer's disease (AD). "
10/01/2009 - "Addressing Alzheimer's disease tangles: from NAP to AL-108."
07/01/2008 - "AL-108 is undergoing phase II trials for cognitive impairment in Alzheimer's disease and schizophrenia. "
01/01/2011 - "Protection against tauopathy by the drug candidates NAP (davunetide) and D-SAL: biochemical, cellular and behavioral aspects."
07/01/2013 - "NAP (davunetide) rescues neuronal dysfunction in a Drosophila model of tauopathy."
11/01/2012 - "ADNP haploinsufficiency in mice results in tauopathy and cognitive deficits ameliorated by davunetide treatment. "
11/01/2012 - "Davunetide (NAP) is a leading drug candidate being tested against tauopathy. "
01/01/2011 - "In conclusion, NAP (davunetide) provided potent neuroprotection in a broad range of neurodegenerative models, protecting the neuroglial cytoskeleton in vitro and inhibiting tau pathology (tauopathy) in vivo. "
06/01/2011 - "In the present study, we have investigated the antioxidant and memory protection efficacy of the synthetic NAP peptide (NAPVSIPQ) during long-term chronic hypobaric hypoxia (7, 14, 21 and 28 days, 25,000ft) in rats. "
11/01/2014 - "Protein profiling reveals antioxidant and signaling activities of NAP (Davunetide) in rodent hippocampus exposed to hypobaric hypoxia."
06/01/2011 - "These cumulative results suggest the therapeutic potential of NAP peptide for ameliorating hypobaric hypoxia-induced oxidative stress."
|5.||Neurodegenerative Diseases (Neurodegenerative Disease)
09/01/2013 - "Davunetide: a review of safety and efficacy data with a focus on neurodegenerative diseases."
05/01/2010 - "Activity-dependent neuroprotective protein (ADNP) plays an essential role in brain development, and NAP (NAPVSIPQ, generic name: davunetide)--a peptide derived from ADNP--is currently in clinical development for the treatment of neurodegenerative disorders. "
12/01/2010 - "It is hoped that davunetide, a most advanced drug in clinical development will rapidly advance as a first effective treatment for a number of brain disorders broadly categorized as frontotemporal dementia (FTD) and serve as a prototype for future therapeutic development toward modification and remedy of currently intractable neurodegenerative diseases."
09/01/2013 - "Potential clinical uses of davunetide include neurodegenerative disorders such as Alzheimer's disease (AD), progressive supranuclear palsy (PSP), frontotemporal dementia (FTD) or cognitive impairment in other diseases such as schizophrenia where microtubule structure and function is known to be impaired. "
|1.||Glutathione Disulfide (GSSG)
|2.||Kainic Acid (Kainate)
|3.||Choline (Choline Chloride)
|4.||N-acetylaspartate (N-acetyl aspartate)
|3.||Coronary Artery Bypass (Coronary Artery Bypass Surgery)
|4.||Activities of Daily Living (ADL)